The net sales of the Biohit Group tota

Report this content
BIOHIT OYJ      STOCK EXCHANGE RELEASE        6.11.2002    AT 10:00
The  net  sales of the Biohit Group totalled MEUR 18.9 (MEUR  18.7  1-
9/2001), the operating loss before goodwill amortization was MEUR 0.2 
(MEUR 1.3  profit)  and the loss for the period MEUR 1.1 (MEUR 0.1  profit).
Biohit  continued investing strongly in research and  development  and
especially   in  the  evaluations  and  international   marketing   of
diagnostic products.

Net Sales

The  net  sales of the Biohit Group for the reporting period  totalled
MEUR  18.9 (MEUR 18.7), i.e., demonstrating a 1% growth. The net sales
were  generated  primarily by the sales of liquid  handling  products,
their  disposable  tips as well as maintenance services.  Primarily  a
decrease  in  the sales of liquid handling products in  the  U.S.  and
German  markets slowed down the growth of the group net sales.  During
the  reporting period Biohit received the first major orders  for  the


The  operating  loss before goodwill amortization for the  period  was
MEUR 0.2 (MEUR 1.3 profit). During the last quarter of the period  the
profit  before  goodwill amortization was MEUR  0.1  (MEUR  0.5).  The
operating  loss was MEUR 0.7 (MEUR 0.5 profit), and the loss  for  the
period  MEUR 1.1 (MEUR 0.1 profit). The income taxes (MEUR  0.2)  have
been accounted for on the basis of the result for the period. However,
deferred  tax  assets  relating to the taxable losses  have  not  been
accounted for.

The  board  of  Biohit has 27.8.2002 decided to prolong  the  goodwill
amortization period related to Locus genex Oy from seven to 20  years.
The  decision of this change is based on the information on the market
and,  e.g.,  on the feedback of GastroPanel evaluations, according  to
which  the  company estimates that the accumulated  income  effect  is
longer  than  it  was  estimated at first,  and  at  least  20  years.
According  to  the board decision there will be no amortizations  from
the  Locus  genex  goodwill during the last half  of  the  year  2002,
because the amortization according to plan (MEUR 0.4) was based on the
original 7 years' write-off period.

The  additional  investments  made in the  launch  of  the  diagnostic
business  continued  to weaken the group result, in  addition  to  the
stagnation  of the U.S. and German markets. These upfront  investments
are  very typical for biotechnology companies. Since the products  are
finished  and  the application procedures of approvals by  authorities
and  the establishment of sales channels have proceeded favorably,  it
is  expected  that  the investments made will in  the  future  have  a
positive effect on the development of the Group result.

Balance Sheet

As  a  result  of  the dissolution of Locus genex Oy,  the  subsidiary
company  specializing in diagnostics, the balance sheet  of  September
30,2002  includes  a  deferred  tax  receivable  of  MEUR  1.1   under


The  cash  flow provided by operating activities during the  reporting
period  was approx. MEUR 0.6 negative (MEUR 1.5 positive).  The  cash
flow  from  operating activities was weakened considerably during  the
period  by  the  payment  of  2001  taxes  related  to  the  voluntary
dissolution of Locus genex Oy. The Group's liquid assets totalled MEUR
1.0  (MEUR  2.6) at the end of the reporting period. The equity  ratio
was 69.2 % (66.7 %) at the end of the reporting period.


The  gross investments of the reporting period totalled MEUR 1.3 (MEUR
1.5).  The  major  part  of  the investments consisted  of  machinery,
equipment and injection moulding tools for improving the efficiency of
production,  and  patent  costs.  During  the  reporting  period   the
expansion of the production premises for diagnostics was completed  at
the Helsinki office.


The  average  number  of personnel totalled 306 during  the  reporting
period  (285  during the corresponding period in 2001), of  which  185
were  employed  by the parent company (174 in 2001)  and  121  by  the
subsidiaries  (111 in 2001). The increase in personnel  resulted  from
investments  made  in 2001 in research & development,  production,  as
well  as  personnel  increases  in  subsidiaries  made  to  strengthen
internation sales.

Main Events of the Reporting Period

Liquid Handling

In  the area of liquid handling Biohit continued to broaden its eLINE-
range.  During the reporting period Biohit launched the single-channel
model  for the volume range of 100 - 5000 ul. As a result, the  entire
single-channel  eLINE  -product range has  been  completed.  The  said
single-channel family covers the volume range of 0.2 - 5000 ul.

Biohit's new generation electronic eLINE-range has been developed  for
the  most  demanding liquid handling applications. The microprocessor-
control   and  novel  construction  enable  maximum  liquid   handling
performance  with  very  high levels of accuracy  and  precision.  The
ergonomical  design  of the eLINE-range together with  electronic  tip
ejection  reduce  considerably the risk  of  work-related  upper  limb

During  the reporting period the accredited calibration laboratory  of
Biohit  was  certified  in  accordance with  the  ISO  17025  -quality
standard.  Moreover, the capacity of the plastics  production  at  the
plant  in  Kajaani  was increased considerably and the  automation  of
production was continued.


The  evaluations of the test panel for determining Helicobacter pylori
-infection  and  atrophic  gastritis and for  screening  the  risk  of
gastric  cancer  and  peptic  ulcer from blood  samples  (GastroPanel)
continued according to plans.

By  the  end of the reporting period ten clinical evaluations  related
with  the  GastroPanel had been completed in Europe, four in Asia  and
one   in  North  America.  The  number  of  patients  studied  in  the
evaluations   totalled  2,916.  During  the  reporting  period   eight
evaluations were in progress in Europe, two in Africa, one in Asia and
one  in  the Near East. The number of patients to be studied in  these
evaluations  totals  4,520.  By  the  end  of  the  reporting   period
agreements  had been made to commence ten new evaluations  in  Europe,
three in North America and one in Asia.

During  the  reporting  period Biohit received the  first  significant
customer   orders   for  the  GastroPanel  test.  Moreover,   numerous
distribution agreements were concluded for Biohit's diagnostic product
range.  During the reporting period the GastroPanel was  used  at  the
Jorvi  Hospital  (HUCH: The Helsinki University Central  Hospital)  in
Finland and in two service laboratories in Finland and in Germany.

Biohit  is expecting to conclude an agreement before the end  of  2002
with  a leading pharmaceutical company who will market the GastroPanel
in conjunction with their drugs for patients with dyspepsia. This will
enable  general practitioners (GP's) and hospital specialists  to  use
the  principles  of  "evidence-based medicine"  as  a  more  desirable
alternative   to  the  empirical  prescription  of   drugs   -   often
unnecessarily, which has been the case until now. This  close  linking
and   co-marketing   of  drug  prescribing  and   diagnostics,   i.e.,
"theranostics" is expected to increase rapidly in the future as  novel
diagnostic tests such as GastroPanel are developed.

In  the  area  of diagnostics Biohit was awarded during the  reporting
period  the  U.S. patent 6,416,961 for the Diagnosis of Early  Gastric
Cancer  (July 9, 2002) and the European patent 0804737 for the  Method
for  Screening  the Risk of Gastric Cancer (Feb. 13, 2002).  Moreover,
Biohit  was  awarded  the European patent 0812421  for  a  method  for
diagnosing  systemic lupus erythematosus (SLE). SLE  is  a  connective
tissue   disease,  which  resembles  rheumatic  diseases.   Additional
information on the GastroPanel is provided at the end of this release.

Subscription of Shares on the Basis of Option Rights

On  the basis of Biohit's personnel option program 1999 and the option
program 1999/II targeted to Jencons Scientific Ltd. altogether 294,250
B-shares of Biohit were subscribed between 1.1.-30.9.2002.

Increases in Share Capital

As  a  result of the subscription of shares made on the basis  of  the
1999  personnel  option  program and the option  program  targeted  to
Jencons Scientific Ltd., the share capital of Biohit increased  during
the  reporting  period  by  EUR  50,022.50  (294,250  shares)  to  EUR
2,199,396.59 (12,937,627 shares). The share premium of EUR  518,657.50
has been recorded in the premium fund.

Equity Turnover and Price Development

The  turnover  of  Biohit's B-shares on the NM-list  of  the  Helsinki
Exchanges was during the reporting period EUR 2,551,919 and the number
of  shares 893,864. The highest price was EUR 4.40 and the lowest  EUR
1.72. The average price was EUR 2.85.

Prospects for 2002

Biohit  estimates  that the net sales of the group for  2002  will  be
generated primarily by the sales of liquid handling products, and that
the  net  sales will increase approx. 2-3%. It is estimated  that  the
result after taxes for year 2002 will be negative.

The most important factors affecting the development of the result  of
Biohit  are the development of the liquid handling product  market  in
the  U.S.  and  Germany. However, as Biohit is concluding  significant
marketing agreements, it is estimated that the diagnostics sales  will
increase substantially this year.

In order to improve the development of the result Biohit took into use
an  adaptation  program  of its activities.  In  accordance  with  the
program the company aims, e.g., to intensify marketing efforts and cut
costs.  The  measures  to cut costs included  also  the  reduction  of
personnel by temporary dismissals. The related industrial co-operation
procedure  began in August 2002. The industrial co-operation procedure
affected  altogether  22  persons. This personnel  will  be  partially
dismissed and partially the employment contract will be terminated  as
a result of externalization or early retirement.

Group Income Statement

                             1-9      1-9   Change   Change  1-12/01
                            2002     2001     MEUR        %     MEUR
                            MEUR     MEUR     		       
Net sales                   18.9     18.7      0.2        1     25.5
Operating expenses         -17.9    -16.6      1.3        8    -23.0
Depreciation excluding                                              
 goodwill amortization      -1.1     -0.9      0.2       27     -1.3
Operating profit/loss                                               
before goodwill                                                     
amortization                -0.2      1.3     -1.5     -113      1.2
Amortization on                                                     
 goodwill                   -0.6     -0.7     -0.1      -25     -1.0
Operating profit/loss       -0.7      0.5     -1.2     -239      0.2
Financial expenses                                                  
 (net)                      -0.2      0.1     -0.1       21     -0.2
Profit/loss before                                                  
 extraordinary items        -0.9      0.4     -1.3     -334      0.1
Extraordinary income         0.0      0.0      0.0        0      0.0
Extraordinary expenses       0.0      0.0      0.0        0      0.0
Profit/loss before                                                  
 taxes                      -0.9      0.4     -1.1     -334      0.1
Profit/loss for the                                                 
 period                     -1.1      0.1     -1.2    -1833     -0.2

Group Balance Sheet

                        30.9.2002       30.9.2001        31.12.2001
                      MEUR        %    MEUR       %    MEUR        %
Non-current assets    11.0       48    11.3      45    11.4       46
Current assets                                                      
 Inventories           3.9       17     4.2      17     4.3       17
 Receivables           6.8       30     7.0      28     6.8       27
 Cash and cash                                                      
  equivalents          1.0        5     2.6      10     2.5       10
Total assets          22.7      100    25.1     100    25.0      100
Liabilities and                                                     
  Share capital        2.2       10     2.2       9     2.2        9
  Share premium                                                     
fund                  15.4       67    14.9      59    14.9       60
   profits/losses     -2.1       -9    -0.6      -2    -0.8       -3
  Capital loans        1.2        5     1.2       5     1.2        5
Minority interest      0.1        0     0.1       0     0.1        0
 liabilities           2.4       11     2.3       9     2.1        8
 liabilities           3.5       16     5.0      20     5.3       21
Total liabilities                                                   
and shareholders'
equity                22.7      100    25.1     100    25.0      100

Cash Flow

                           1-9/02   1-9/01  Change  1-12/01
                             MEUR     MEUR    MEUR     MEUR
Cash Flows from                                            
operating activities
Profit/loss before           -0.9      0.4    -1.3      0.1
extraordinary items
Adjustments                   1.9      1.8     0.1      2.4
Change in net working        -0.2     -0.3     0.1     -0.1
Interest and other           -0.2     -0.3     0.1     -0.4
financial items paid
Interests received            0.0      0.1    -0.1      0.1
Income taxes paid            -1.2     -0.2    -1.0     -0.2
Net cash flow from           -0.6      1.5    -2.1      1.9
operating activities
Net cash flow from                                         
investing activities:
Investments in tangible      -1.5     -1.5     0.0     -2.2
and intangible assets
Grants received               0.1      0.0     0.1      0.4
Net cash flow from           -1.4     -1.5     0.1     -1.8
investing activities
Net cash flow from                                         
financing activities
Proceeds from share           0.6      0.0     0.6        0
Increase in long-term         0.4      0.1     0.3      0.1
Repayments of long-term      -0.4     -0.7     0.3     -0.9
Increase in capital           0.0      0.1    -0.1      0.1
Net cash flow from            0.6     -0.5     1.1     -0.7
financing activities
Net increase                 -1.4     -0.5    -0.9     -0.6
(+)/decrease (-)in cash
and cash equivalents
Cash and cash                 2.4      3.0    -0.6      3.0
equivalents 1.1.
Cash and cash                 1.0      2.5    -1.5      2.4
equivalents at the end of
the period

                              1-9      1-9 Change    Change  1-12/01
                             2002     2001   MEUR         %     MEUR
Investments, gross MEUR       1.3      1.5   -0.2       -13      2.1
   % net sales                7.1      8.2                       8.7
Employees, average            306      285     21         7      289

Pledges given, commitments and contingencies

                                 30.9.2002     30.9.2001   31.12.2001
Loans for which pledges               MEUR          MEUR         MEUR
 have been given                                                     
Loans from financial                                                 
 Institutions                          1.7           2.1          1.9
  Corporate mortgages                  3.4           3.4          3.4
Other long-term liabilities            0.8           0.8          0.8
  Mortgages                            0.8           0.8          0.8
Leasing commitments                    4.2           3.7          4.0

Interest on Capital Loans

The unrecorded interest accrued on capital loans on 30.9.2002 totalled
MEUR 0.5 and on 31.12.2001 MEUR 0.4.

                                 30.9.2002     30.9.2001   31.12.2001
  Equity ratio, %                     69.2          66.7         65.7
  Earnings per share, EUR            -0.08          0.00        -0.02
  Shareholders' equity                                               
   per share, EUR                     1.20          1.30         1.28
Average number of shares        12,790,763    12,643,377   12,643,377
Number of shares at the                                              
 end of the period              12,937,627    12,643,377   12,643,377

Derivative Contracts

The Group does not have any off balance sheet financial instruments.

The figures of the Interim Report are unaudited.

Helsinki, November 6, 2002

Board of Directors of Biohit Oyj

Overview on Biohit

Biohit,  operating in the areas of biotechnology and high  technology,
develops,  manufactures  and  markets  liquid  handling  products  and
accessories  as well as diagnostic test systems for use  in  research,
health care and industrial laboratories.

In  the  area of liquid handling Biohit's main products are electronic
and   mechanical  pipettors  and  their  disposable  tips.  Currently,
Biohit's range of electronic and mechanical pipettors is the widest in
the  world.  Biohit  is  also the global market leader  of  electronic

In  the  area of diagnostics Biohit develops, manufactures and markets
test kits based on the enzyme immunoassay (EIA) -method and monoclonal
antibodies  for  the  diagnosing and screening of different  types  of
disease.  Biohit's  diagnostic product range includes,  e.g.,  a  test
panel  for  diagnosing and screening H.pylori -infection and  atrophic
gastritis  as  well  as for assessing the risk of gastric  cancer  and
peptic  ulcer from blood samples (the GastroPanel), as well  as  tests
for   the   detection  of  lactose  intolerance  and  systemic   lupus
erythematosus (SLE).

In  order  to  be  able to offer complete analyzing  systems  for  its
customer base, Biohit's product range includes, in addition to  liquid
handling  products and diagnostics, instruments used for the  analysis
of  test results. Moreover, Biohit offers as a part of its product and
marketing  strategy  maintenance, calibration  and  training  services
through the Group companies and its distributors.

Biohit's  production plants are located in Kajaani and  Helsinki.  The
sales  and  marketing  subsidiaries are located  in  France,  Germany,
Italy,  Japan,  Russia,  the  U.K. and the U.S.  Biohit's  distributor
network covers altogether approx. 450 members and 70 countries.

Moreover,  many  multinational companies,  such  as  Beckman  Coulter,
Becton  Dickinson,  bioMérieux, Johnson & Johnson  and  3M  complement
their  diagnostic  systems  with Biohit's electronic  liquid  handling
products. As to Group net sales, 96% are generated outside of Finland,
and the degree of domestic production is approx. 95%.

The GastroPanel Examination, Areas of Use and Its Utility

One  third  of  the  global  population suffers  from  dyspepsia,  the
occasional or continuous pain or discomfort in the upper part  of  the
abdomen.  Over  half of the cases of dyspepsia are  functional,  which
means  that  the  mucosa  of  the stomach functions  normally  and  is
healthy. However, dyspepsia may be related to severe gastric illnesses
which  are associated with gastritis and impaired functions of mucosal
glands, i.e., with atrophic gastritis.

Atrophic  gastritis, which is symptomless or shows only weak symptoms,
is  a  disease  which develops gradually and associates  with  various
gastric diseases. Often atrophic gastritis is not diagnosed at all, or
it is diagnosed at a late stage. It is commonly believed that atrophic
gastritis  is irreversible. However, most recent research results  and
clinical  experience indicate that gastric atrophy is  reversible  and
that it is possible to treat and cure atrophic gastritis.

If  atrophic  gastritis is diagnosed and treated the risk  of  gastric
cancer  and peptic ulcer decreases. Atrophic gastiris and the  related
deficiency of vitamin B12, if untreated, may be the causes that worsen
dementia, damages of the peripheral nervous system, and raise the risk
of heart and brain strokes.

So   far  gastroscopy  with  gastric  histology  have  been  the  only
diagnostic  methods  for  atrophic  gastritis.  Biohit  has  developed
together with scientists the GastroPanel-test which enables to  screen
and diagnose atrophic gastritis from a blood sample (

The  Helicobacter pylori -infection is one of the most common  chronic
infections, which causes severe gastric diseases all over  the  world.
All  persons  suffering  from the H. pylori  -infection  will  develop
chronic gastritis. Approximately half of the world population  has  H.
pylori -infection, and over 20% of the infected may suffer from peptic
ulcer during their lifetime.

Half  of  those  infected with H. pylori will get atrophic  gastritis.
This,  on its part, increases considerably the risk of gastric cancer.
Approx.  10%  of  the patients with H. pylori -related gastritis  will
develop  severe atrophic gastritis of the corpus area of the  stomach.
These  patients are at a very high risk of developing diseases related
with the deficiency of vitamin B12.

The Maastricht 2 (2000) consensus recommends that symptomatic patients
with  H.pylori are to be treated, and it is recommended further  that,
in order to prevent severe complications, the patients with H.pylori -
infection  and major gastric pathology (atrophic gastritis),  with  or
without  symptoms,  should  be treated for  H.pylori.  These  patients
should  also  undergo a diagnostic endoscopy. At an early asymptomatic
stage, up to 4-6% of such patients are reported to have definite,  but
curable, cancerous or precancerous gastric lesions.


GastroPanel enables the diagnosis of H. pylori -infection and atrophic
gastritis as well as enables to screen by a blood test the subjects at
risk  for  gastric cancer and peptic ulcer. On the basis of the  serum
levels of Pepsinogen I and Gastrin-17 as well as Helicobacter pylori -
antibodies  it is possible to establish if the patient has  gastritis,
whether  the  gastritis is atrophic or not, and in which part  of  the
stomach  (antrum,  corpus or both) the changes are  located.  Patients
suffering from atrophic gastritis are at risk for disorders related to
the  deficiency  of  vitamin B12. The tests are based  on  the  enzyme
immunoassay (EIA) -method. Among dyspeptic patients the GastroPanel is
a non-invasive alternative for gastroscopy and gastric histology.


Biohit  has developed the GastroSoft, an easy-to-use computer program,
for  the  interpretation  of  the results of  the  GastroPanel  assays
( This program draws up a diagnosis  of  H.
pylori -infection and possible atrophic gastritis, and gives estimates
of risks for gastric cancer and peptic ulcer. In addition, the program
gives a recommendation for the treatment of H. pylori -infection based
on  the  Maastricht 2 (2000) consensus. The program  further  gives  a
recommendation whether gastroscopy and the measurement  of  the  serum
levels of vitamin B12 and homocysteine are necessary. Depending on the
symptoms  and  the  results  produced by the  GastroPanel,  GastroSoft
reminds of possible risks of reflux disease and Barrett's esophagus.

Areas of Use of the GastroPanel

GastroPanel  enables  the  diagnosis of  atrophic  gastritis  and  the
screening of patients with the gastritis-related diseases. The testing
by  GastroPanel helps to draw up the accurate diagnosis and  promotes,
thereby,  the  objectivity in the clinical conclusions  and  decision-
making  (evidence-based medicine) more than is possible to do  in  the
basis of symptoms and H. pylori testing alone.

GastroPanel is useful in:

1)  Diagnosis of dyspepsia, i.e., pain or discomfort in the upper part
of  the  abdomen (prevalence of dyspepsia: approx. 30% of  the  global
-     Functional dyspepsia (over half of dyspeptic cases). The results
  produced by GastroPanel and gastroscopy indicate that the mucosa  of
  the  stomach is normal (no atrophy, no inflammation, no H. pylori  -
-    Dyspepsia with H. pylori -infection and non-atrophic gastritis
(prevalence in approx. 30-50% of the population in Western countries)
-     Dyspepsia with organic diseases. In these cases the findings  of
  the  GatroPanel are nearly always pathological. Possible causes are,
  e.g.,  atrophic  gastritis, gastric cancer, peptic ulcer  or  reflux
  disease.  Prevalence of reflux disease: Approx. 20%  of  the  global
-    The risk of Barrett's disease can be assessed with the

2)   Diagnosis of H. pylori -infection (prevalence on the average over
  50%  of  the  global population) and atrophic gastritis  (prevalence
  approx. half of those infected by H. pylori). The assessment of  the
  risk  of  gastric cancer (prevalence approx. 0,1%) and peptic  ulcer
  (prevalence approx. 10%).

3)    Screening  and  diagnosis  of corpus  atrophy,  which  causes  a
  deficiency of vitamin B12. The deficiency may increase the risk  of,
  e.g.,  dementia, depression and polyneuropathies (  The
  diseases related with the deficiency of vitamin B12 begin to develop
  before any signs of pernicious anemia. It has been reported that the
  low   vitamin   B12   related  neurodegenerative  disorders   become
  irreversible  if  the diagnosis and treatment of the  deficiency  of
  vitamin B12 are delayed. As many as 30% of persons over 65 years may
  suffer from the deficiency of vitamin B12.

  The  deficiency of vitamin B12 is one cause for increasing the level
  of homocysteine in the body, which is an independent risk factor for
  atherosclerosis and heart and brain strokes (

Utility of the GastroPanel

Thus  far, gastroscopy and the microscopic examination of the  gastric
biopsy have been the only methods to diagnose atrophic gastritis.  The
GastroPanel is intended to screen and diagnose atrophic gastritis from
a blood sample.

The  GastroPanel  enables  to  find  atrophic  gastritis  and  related
diseases.  In addition, the GastroPanel helps to assess the  need  and
urgency of gastroscopy and the gastric biopsy.

The   early   diagnosis  of  atrophic  gastritis  and  the  subsequent
eradication  of  the  H.  pylori  -infection  is  the  basis  for  the
prevention of the diseases related to atrophic gastritis.

The  use of the GastroPanel improves the level of diagnostics and  the
treatment of patients with dyspepsia. It has been estimated  that  the
use  of the GastroPanel in Finland could save several hundred millions
(EUR) in health care costs if the benefits of the prevention and early
treatment  of  the dyspepsia and atrophic gastritis -related  diseases
are taken into consideration.

The  GastroPanel kit comprising the tests for Pepsinogen I, H.  pylori
and  Gastrin-17 enables the analysis of 50 patients. The taxless  end-
user price in Finland for the GastroPanel kit is EUR 1,080. Thus,  the
cost  of examining one patient with the GastroPanel is approx. EUR  20
for  a  health  care center or a private laboratory. In addition,  the
cost of the work related with sample taking and analyses totals EUR 15-
20.  The  price includes the GastroSoft program which interpretes  the
results  of the GastroPanel. The most recent version of the GastroSoft
program    can    be   tested   and   loaded   from    the    internet

Gastroscopy is currently the only alternative for the GastroPanel test
in  the diagnosis of atrophic gastritis. In Finland commercial service
laboratories charge EUR 65 for the GastroPanel examination whereas the
price   of  gastroscopy  with  histology  is  approx.  EUR  300,   and
considerably more if special arrangements, e.g., various sedations are
needed  and  used.  In addition, possible complications  related  with
gastroscopy such as mortality (0.0025% - 0.05%), perforation  (0.03%),
hemorrhage (0.01 - 0.1%) and inflammations (3-4%), raise the costs.
It  has  been  estimated  that altogether  100,000  gastroscopies  are
performed  in Finland annually mainly for various dyspeptic  symptoms.
Atrophic gastritis is diagnosed in nearly half of the patients with H.
pylori  -infection,  in  old  age groups  in  particular.  It  can  be
estimated  that  100,000 gastroscopies are not enough  to  fulfil  the
clinical  needs.  The  GastroPanel as a cost efficient  and  risk-free
method  is  a conceivable tool or alternative as a primary  diagnostic
mean   when  determining  the  severity  of  dyspepsia  and   atrophic

The  GastroPanel-test,  if  made before the gastroscopy,  enables  the
differentiation between patients with non-atrophic gastritis and those
with  atrophic gastritis. The GastroPanel provides information on  the
severity  and  typographic  location  of  atrophic  gastritis  in  the
stomach.  Moreover,  the GastroPanel enables to  establish  with  high
reliability  whether the mucosa of the stomach is normal and  healthy.
In  such  patients with healthy gastric mucosa the risk  of  all  main
gastric  diseases (gastric cancer and peptic ulcer) is  very  low.  In
everyday  practice in Finland today approx. 50% of  the  patients  who
undergo gastroscopy have a normal and healthy stomach.

When  taking  into  consideration the need  for  gastric  examinations
within  the  areas of clinical diagnostics, screening applications  as
well  as  follow-up  and  routine studies (occupational  health  care,
patients  at risk, the elderly, patients suffering from the deficiency
of vitamin B12) it can be estimated that more than 500,000 GastroPanel
examinations are needed in Finland annually.

Biohit Oyj
Helena Hentola
Corporate Communications

Additional information:  Osmo  Suovaniemi, Professor, President & CEO,
                         tel:  +358-9-773 861, direct:  +358-9-773  86
                         250,  mobile: +358-40 745 5605, fax:  +358-9-
                         773 86 205,


Distribution:            The Helsinki Exchanges
                         The Financial Supervisory Authority